BridgeMD
Accelerated treatment of infectious endocarditis
EU CTIS ID: 2023-507652-76-00
What this study is testing
To study safety and efficacy of a shorter course of antibiotic treatment for infectious endocarditis. Specifically, the study evaluates acellerated antibiotic treatment for left-sided endocarditis caused by any of the bacterial species Staphylococcus aureus, Enterococcus faecalis or streptococci.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age >18 years. 2. In-patient at a hospital ward. 3. Left-sided endocarditis according to modified Duke's criteria. 4. Verified infection with Stapylococcus aureus, streptococci or Enterococcus faecalis. 5. Obtained informed consent.
You likely can't join if
- 1. Known or suspected immunosuppression such as HIV-infection, ongoing chemotherapy or treatment with corticosteroids in a dose exceeding 20 mg prednisone per day. 2. Unable to give informed consent. 3. Relapse of endocarditis defined as endocarditis caused by the same bacteria within 6 months after a preceeding infection. 4. Endocarditis caused by Staphylococcus aureus in a patient with prosthetic heart valve or cardiovascular implanted device.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.